{"id":"W4416589081","doi":"10.1016/s1470-2045(25)00543-1","title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Jiangsu Hengrui Medicine","keywords":"Hepatocellular carcinoma; Sorafenib; Overall survival; Phases of clinical research; Phase (matter); Clinical trial; Carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003193644,0.001747284,0.003313763,0.0004730084,0.0003896124,0.001369527,0.0008152665,0.001434857,0.004983447],"category_scores_gemma":[0.002670045,0.0007083876,0.004482632,0.0005673054,0.001466382,0.001520317,0.0004565937,0.003655556,0.001036878],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001417307,"about_ca_system_score_gemma":0.00134535,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001866078,"about_ca_topic_score_gemma":0.004427842,"domain_scores_codex":[0.9988702,0.0006783052,0.0000552651,0.0001494306,0.00007295341,0.0001738106],"domain_scores_gemma":[0.9984908,0.0005405163,0.0003261394,0.0001456674,0.00008467754,0.0004122521],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.977632,0.001789979,0.000620377,0.0005494126,0.001672427,0.00002561561,0.00004665918,0.0006053688,0.001071061,0.00009777353,0.0009853062,0.01490408],"study_design_scores_gemma":[0.9484435,0.04662549,0.00240006,0.00004753171,0.0009827347,0.00004484609,0.00003258136,0.0004720608,0.0002255447,0.0002129169,0.0004920654,0.00002058705],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9830754,0.008705404,0.0007988554,0.0009995695,0.0006287131,0.001439044,0.001811892,0.0002018128,0.002339233],"genre_scores_gemma":[0.98843,0.003275263,0.00147325,0.001052681,0.0003934926,0.001135148,0.001951632,0.00004354845,0.002245056],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004983447,"threshold_uncertainty_score":0.01688981,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.253640716663586,"score_gpt":0.4308349151827485,"score_spread":0.1771941985191625,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}